MedTrace Logo

Serum Biomarkers in Diagnosis of Mesothelioma

NCT02029105 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2014-01-07

No results posted yet for this study

Summary

In this study, the investigators analyzed the efficiencies of hyaluronan, osteopontin, C-ERC/mesothelin, N-ERC/mesothelin and syndecan-1 serum levels, both individually and in combination, in distinguishing malignant pleural mesothelioma patients from patients with metastatic malignant pleural diseases, benign pleural diseases, and benign asbestos pleurisy.

Conditions

Interventions

BIOLOGICAL

Mesothelin, hyaluronan, osteopontin, syndecan-1

We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.

Sponsors & Collaborators

  • Eskisehir Osmangazi University

    lead OTHER

Principal Investigators

  • Muzaffer Metintas, Prof.Dr. · Eskisehir Osmangazi University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2010-12-31
Completion
2013-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02029105 on ClinicalTrials.gov